PharmaMar’s core business is oncology and it fully owns other companies that cover different aspects of healthcare.

Biopharmaceutical Sector

As a global company, GENOMICA is focused on developing in vitro molecular diagnostics that are efficient tools for detection of infectious diseases and cancer mutations in clinical practice anticancer therapies.

As an emerging business in the field of RNAi-derived drugs, Sylentis is developing a novel RNAi platform to address unmet medical needs in the area of ocular diseases.